Amit Sachdev Sells 32,422 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Amit Sachdev sold 32,422 shares of Vertex Pharmaceuticals stock in a transaction on Friday, January 19th. The shares were sold at an average price of $158.08, for a total transaction of $5,125,269.76. Following the completion of the sale, the executive vice president now directly owns 57,835 shares of the company’s stock, valued at approximately $9,142,556.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Amit Sachdev also recently made the following trade(s):

  • On Monday, February 5th, Amit Sachdev sold 4,520 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $163.01, for a total transaction of $736,805.20.
  • On Monday, January 29th, Amit Sachdev sold 15,085 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $170.00, for a total value of $2,564,450.00.
  • On Monday, January 22nd, Amit Sachdev sold 46,172 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $158.65, for a total value of $7,325,187.80.
  • On Tuesday, October 31st, Amit Sachdev sold 40,000 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $145.05, for a total value of $5,802,000.00.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded up $1.97 during trading hours on Thursday, reaching $159.23. The company had a trading volume of 249,383 shares, compared to its average volume of 2,018,948. The company has a market cap of $39,770.00, a P/E ratio of 81.66, a price-to-earnings-growth ratio of 2.25 and a beta of 1.61. Vertex Pharmaceuticals Incorporated has a one year low of $84.39 and a one year high of $174.96. The company has a quick ratio of 4.58, a current ratio of 4.79 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.08. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. The company had revenue of $651.63 million during the quarter, compared to the consensus estimate of $592.49 million. During the same quarter in the previous year, the company posted $0.35 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 42.1% compared to the same quarter last year. research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 1.63 EPS for the current fiscal year.

Vertex Pharmaceuticals announced that its Board of Directors has authorized a stock buyback plan on Wednesday, January 31st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the pharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

VRTX has been the topic of a number of recent analyst reports. Deutsche Bank initiated coverage on Vertex Pharmaceuticals in a research note on Tuesday, December 12th. They set a “buy” rating and a $175.00 target price on the stock. Cowen reiterated a “buy” rating and set a $200.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, December 11th. Royal Bank of Canada reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Needham & Company LLC reissued a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Finally, Robert W. Baird reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, three have given a hold rating and twenty-five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $183.11.

A number of hedge funds have recently made changes to their positions in the business. Jennison Associates LLC lifted its position in Vertex Pharmaceuticals by 19.0% in the third quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock valued at $914,941,000 after purchasing an additional 962,644 shares during the last quarter. Renaissance Technologies LLC lifted its position in Vertex Pharmaceuticals by 108.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,847,917 shares of the pharmaceutical company’s stock valued at $426,789,000 after purchasing an additional 1,479,897 shares during the last quarter. Geode Capital Management LLC lifted its position in Vertex Pharmaceuticals by 4.2% in the fourth quarter. Geode Capital Management LLC now owns 2,607,251 shares of the pharmaceutical company’s stock valued at $389,878,000 after purchasing an additional 105,683 shares during the last quarter. Wells Fargo & Company MN lifted its position in Vertex Pharmaceuticals by 7.6% in the fourth quarter. Wells Fargo & Company MN now owns 2,127,092 shares of the pharmaceutical company’s stock valued at $318,765,000 after purchasing an additional 149,823 shares during the last quarter. Finally, Orbimed Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 2.4% during the third quarter. Orbimed Advisors LLC now owns 2,074,302 shares of the pharmaceutical company’s stock valued at $315,377,000 after acquiring an additional 47,800 shares in the last quarter. Hedge funds and other institutional investors own 92.84% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://weekherald.com/2018/02/15/amit-sachdev-sells-32422-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply